Meeting
2017 ASCO Annual Meeting
PRKDC: A new candidate for checkpoint blockade immunotherapy?
Authors
Ming Huang Chen
Taipei Veterans General Hospital, Taipei, Taiwan
Ming Huang Chen , Kien Thiam Tan , Jen Hao Cheng , Wen-Liang Fang , Yi Chen Yeh , Chun-Nan Yeh , Yu Chan Chang , Shu-Jen Chen , Michael Hsiao , Yee Chao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research,Immunotherapy
Sub Track
Biomarkers and Correlative Studies from Immunotherapy Trials
Citation
J Clin Oncol 35, 2017 (suppl; abstr 3022)
DOI
10.1200/JCO.2017.35.15_suppl.3022
Abstract #
3022
Poster Bd #
117
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Characterization of NY-ESO-1 gene expression in gastric cancer (GC).
First Author: Annika Lenz
Poster
2022 ASCO Annual Meeting
Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types.
First Author: Joan Miguel Romero
First Author: Radhika Gogoi
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
First Author: Jason Zhu